Clinical Trial Update: A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 1b/Phase 2 study evaluating the combination of Alectinib and Cobimetinib in adults with advanced ALK-rearranged non-sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)
• Cotellic (cobimetinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING